CMS Official: Don't expect a lot of fully risk-based payment models going forward

Fierce Healthcare
 
Don’t expect a lot more fully risk-based payment models from the Center for Medicare and Medicaid Innovation (CMMI), a top official said.
 
Centers for Medicare & Medicaid Services Chief Operating Officer Jon Blum detailed the agency’s vision for value-based care during the National Association of Accountable Care Organizations' fall conference Thursday.
 
“I don’t think that CMS will be promoting models that have more risk just for the sake of having more risk,” said Blum.
 
Although Blum said it is still important to have risk-based models, there are data that show downsides of full-risk payment models.
 
“We know that when we [incentivize] risk we see some downsides to that,” Blum said. “We see stronger incentives for more diagnosis code submissions, some of which might be appropriate, some of which not.”
 
Another concern is when you have “more transformation towards risk that tends to favor those who are better capitalized and can afford risk,” he added.
 
ACOs agree to take on a share of financial risk and meet spending and quality benchmarks. ACOs that don’t meet the benchmarks will have to repay Medicare but will get a share of savings if they do.
 
CMS has offered payment models that require providers to take on a high degree of risk. However, one of those models, the Next Generation ACO model, was sunset by the Biden administration.
 
Blum said that doesn't mean CMS won't adopt any high-risk models.

Read Full Article

 

Critical Time Window for Rehabilitation After a Stroke

National Institutes of Health

https://www.nih.gov/news-events/nih-research-matters/critical-time-window-rehabilitation-after-stroke

Every 40 seconds, an American has a stroke. About 750,000 new strokes occur in the United States each year.

Restoring brain function after a stroke remains a challenge. Functional recovery from brain damage requires networks of nerves to adapt and reorganize. This “neuroplasticity” naturally occurs during early development. But studies in rodents suggest that there is a brief period of similarly high neuroplasticity after a stroke. Intensive motor training provided to rodents during this window can lead to nearly full recovery. But no evidence for a similar recovery window in humans has previously been found.

To find out if such a window exists in people, a team led by Dr. Alexander Dromerick of Georgetown University Medical Center and MedStar National Rehabilitation Hospital conducted a randomized phase II clinical trial. NIH’s National Institute of Neurological Disorders and Stroke (NINDS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), and National Institute on Deafness and Other Communication Disorders (NIDCD) supported the study. Results appeared in the Proceedings of the National Academy of Sciences on September 20, 2021.

The researchers recruited 72 patients from a rehabilitation hospital in Washington, DC. They randomly assigned participants to one of four groups. All participants received standard stroke rehabilitation therapy. Those in three of the four groups received an extra 20 hours of intensive motor skills therapy. In the first group, the extra therapy began within 30 days of stroke onset. In the second group, extra therapy began 2-3 months after stroke onset. In the third, it began 6-7 months after stroke onset. Participants in the fourth (control) group received no extra therapy.

The researchers assessed arm and hand function at various points before and after treatment, up to 12 months after stroke onset. People in the 2–3 month therapy group showed the greatest improvement one year after their strokes. Participants in the 30-day group showed smaller but still significant improvement. By contrast, participants in the 6-7 month group showed no significant improvement over controls.

“Our results suggest that more intensive motor rehabilitation should be provided to stroke patients at 60 to 90 days after stroke onset,” co-author Dr. Elissa Newport says.

“Previous clinical trials have found few or very small improvements in motor function post-stroke, so our research could be an important breakthrough in finding ways we can make substantial improvements in arm and hand recovery,” Dromerick says.

The results strongly suggest that there is a critical time window for rehabilitation following a stroke. For this study, that window was 2-3 months after stroke onset. Larger clinical trials are needed to better pin down the timing and duration of this critical window. A larger trial could also determine what dose of therapy would achieve the best results during this window.

—by Brian Doctrow, Ph.D.

References: Critical Period After Stroke Study (CPASS): A phase II clinical trial testing an optimal time for motor recovery after stroke in humans. Dromerick AW, Geed S, Barth J, Brady K, Giannetti ML, Mitchell A, Edwardson MA, Tan MT, Zhou Y, Newport EL, Edwards DF. Proc Natl Acad Sci U S A. 2021 Sep 28;118(39):e2026676118. doi: 10.1073/pnas.2026676118. PMID: 34544853.

 

What Can Providers Give to Patients?

Elizabeth A. Hogue recently sent the series of articles below about what providers can give to patients. Please do not hesitate to contact her at (877) 871-4062 or [email protected] with comments, questions, or requests for additional information.

Copyright, 2021. Elizabeth E. Hogue, Esq. All rights reserved.  No portion of this material may be reproduced in any form without the advance written permission of the author.

Part 1 – Applicable federal statutes and exceptions

Part 2 – Exception for items and services of nominal value

Part 3 – Circumstances under which free items and services may be given to patients who have a demonstrated financial need

Part 4 – Recent OIG guidance regarding incentives to promote COVID-19 vaccination

Part 5 – Exception for preventive items or services

Part 6 – Exception for free items or services that promote access to care

Part 7 – Case example from OIG Advisory Opinion No. 09-11

 

 

Janssen and Moderna COVID-19 Vaccine Boosters Update

The Vaccines and Related Biological Products advisory committee will meet on Oct. 14 and 15  to discuss the use of booster doses of the Janssen and Moderna COVID-19 vaccines Both vaccines are currently authorized for emergency use to prevent COVID-19 in individuals 18 years of age and older. The group will also discuss available data on the use of a booster of a different vaccine than the one used for the primary series.  

Read more in the FDA news release.

 

Placebo Effect

National Center for Complimentary and Integrative Health

The “gold standard” for testing interventions in people is the “randomized, placebo-controlled” clinical trial, in which volunteers are randomly assigned to a test group receiving the experimental intervention or a control group receiving a placebo (an inactive substance that looks like the drug or treatment being tested). Comparing results from the two groups suggests whether changes in the test group result from the treatment or occur by chance.

The placebo effect is a beneficial health outcome resulting from a person’s anticipation that an intervention will help. How a health care provider interacts with a patient also may bring about a positive response that’s independent of any specific treatment.

Research supported by NCCIH has explored several aspects of the placebo effect. One study identified a genetic marker that may predict whether someone will respond to a placebo, another supported the idea that placebo responses may occur outside of conscious awareness, and a third suggested that placebos may be helpful even if patients know they’re receiving placebos.

This publication is not copyrighted and is in the public domain. Duplication is encouraged.

NCCIH has provided this material for your information. It is not intended to substitute for the medical expertise and advice of your health care provider(s). We encourage you to discuss any decisions about treatment or care with your health care provider. The mention of any product, service, or therapy is not an endorsement by NCCIH.

Placebo Effect - Systematic Reviews/Reviews/Meta-analyses (PubMed®)

Placebo Effect - Randomized Controlled Trials (PubMed®)

 
<< first < Prev 81 82 83 84 85 86 87 88 89 90 Next > last >>

Page 84 of 172